Russian President Vladimir Putin, before April 1, instructed the government to study the issue of state support for drug manufacturers in order to avoid shortages after the departure of foreign companies. This is stated in list instructions published on March 7 on the Kremlin website.
The Government of the Russian Federation, taking into account earlier given instructions, should consider the issue of additional measures of state support for developing, conducting clinical trials, manufacturing and launching medicines on the market for companies.
The task of fulfilling the order is to prevent the occurrence of a shortage of medicines due to the risks of foreign pharmaceutical manufacturers leaving the Russian market or suspending their ongoing research.
Prime Minister of the Russian Federation Mikhail Mishustin was appointed responsible for the implementation of the order.
The meeting with the government, following which Putin gave this instruction, took place on January 24. As the head of state noted during it, checks indicate a shortage of certain drugs in Russian pharmacies and an increase in prices for them.
To resolve the issue of shortages, it is necessary to create inventories of the most popular drugs, the president noted.
As Deputy Prime Minister, head of the Ministry of Industry and Trade Denis Manturov noted, Russian pharmaceutical companies produce 82% of vital and essential medicines. According to him, they registered 130 new drugs last year, and the number of clinical trials increased by about 30% compared to 2021.